Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Molecular-genetic imaging: current and future perspectives
Ronald G. Blasberg, Juri Gelovani Tjuvajev
Ronald G. Blasberg, Juri Gelovani Tjuvajev
Published June 1, 2003
Citation Information: J Clin Invest. 2003;111(11):1620-1629. https://doi.org/10.1172/JCI18855.
View: Text | PDF
Perspective

Molecular-genetic imaging: current and future perspectives

  • Text
  • PDF
Abstract

Authors

Ronald G. Blasberg, Juri Gelovani Tjuvajev

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
FDG positron emission tomography (PET) imaging before and after treatmen...
FDG positron emission tomography (PET) imaging before and after treatment. In patients with gastrointestinal stromal tumors (GIST), tumor glucose utilization is very high and these tumors can be readily visualizd by [18F]– fluorodeoxyglucose (FDG) PET (36, 37). A striking observation in patients with GIST who are treated with STI571 (Gleevec) was that the rapid and sustained decrease in fluorodeoxglucose (FDG) uptake determined by PET scan was seen as early as 24 hours after one dose of ST1571, and this was sustained over many months. The high FDG levels seen in the kidney, ureter, and bladder are normal in both the pre- and post-Gleevec images. Figure adapted from ref. 37, with appreciation and permission from Annick Van en Abbeele, Danaa-Farber Cancer Institute, Boston, Massachusetts, USA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts